GLP-1 weight-loss competition remains the center of attention as pharma players continue to push new offerings to compete with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, according to STAT’s market coverage. Reporting also points to what incumbent makers are doing to defend share. Separately, the FDA issued warning letters to 25 telehealth companies over compounded GLP-1 weight loss claims. The agency alleged false or misleading marketing practices, reinforcing that regulatory enforcement will continue to shape how digitally delivered obesity care is sold and prescribed. Together, the two developments highlight both the intensity of product competition and the ongoing scrutiny around non-standard GLP-1 supply models.